InvestSMART

Paradigm Biopharmaceuticals Limited (ASX: PAR) - Announcements

- Current share price for PAR : $0.180

ASX company news and announcements for Paradigm Biopharmaceuticals Limited (PAR) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Paradigm Biopharmaceuticals Limited (PAR) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Paradigm Biopharmaceuticals Limited (PAR), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Paradigm Biopharmaceuticals Limited (PAR)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$108 Trading Halt 15 Apr 2019 9:15AM $1.900 $0.180 fallen by 90.53%
$108 PARADIGMS SECONDARY ENDPOINTS SUCCESSFULLY MET 15 Apr 2019 9:14AM $1.900 $0.180 fallen by 90.53%
$108 Trading Halt 11 Apr 2019 9:04AM $1.900 $0.180 fallen by 90.53%
$108 Response to ASX Price Query 28 Mar 2019 8:59AM $1.980 $0.180 fallen by 90.91%
$108 Paradigm (PAR) Updated Investor Presentation 13 Mar 2019 8:41AM $1.405 $0.180 fallen by 87.19%
$108 Change of Director's Interest Notice 8 Mar 2019 2:30PM $1.305 $0.180 fallen by 86.21%
$108 S&P DJI Announces March 2019 Quarterly Rebalance 8 Mar 2019 8:22AM $1.305 $0.180 fallen by 86.21%
$108 Half Yearly Report and Accounts 21 Feb 2019 6:17PM $1.130 $0.180 fallen by 84.07%
$108 Cleansing Notice and Appendix 3B 14 Feb 2019 5:25PM $1.160 $0.180 fallen by 84.48%
$108 PARADIGMS ORPHAN PHASE 2/3 CLINICAL PROGRAM PROGRESSES 14 Feb 2019 9:41AM $1.195 $0.180 fallen by 84.94%
$108 Appendix 4C - quarterly 31 Jan 2019 4:52PM $1.200 $0.180 fallen by 85%
$108 PARADIGMS SUPPLEMENTARY PHASE 2B DATA 20 Dec 2018 8:40AM $1.210 $0.180 fallen by 85.12%
$108 PRESENTATION OF PHASE 2 CLINICAL TRIAL RESULTS 18 Dec 2018 8:48AM $1.320 $0.180 fallen by 86.36%
$108 PAR REPORTS SUCCESSFUL PHASE 2 CLINICAL TRIAL 18 Dec 2018 8:47AM $1.320 $0.180 fallen by 86.36%
$108 PAR - Conference Call Details - Phase 2b OA Results 17 Dec 2018 11:30AM $1.320 $0.180 fallen by 86.36%
$108 Trading Halt 14 Dec 2018 8:46AM $1.320 $0.180 fallen by 86.36%
$108 Change in substantial holding 13 Dec 2018 1:49PM $1.290 $0.180 fallen by 86.05%
$108 Change of Director's Interest Notice 13 Dec 2018 1:47PM $1.290 $0.180 fallen by 86.05%
$108 Appendix 3B and Cleansing Notice 13 Dec 2018 1:44PM $1.290 $0.180 fallen by 86.05%
$108 PARADIGM REPORTS CONSISTENT OA PAIN REDUCTION 7 Dec 2018 8:30AM $1.260 $0.180 fallen by 85.71%
$108 Cleansing Notice and Appendix 3B 30 Nov 2018 8:20PM $1.145 $0.180 fallen by 84.28%
$108 Cleansing Notice and Appendix 3B 27 Nov 2018 3:34PM $1.270 $0.180 fallen by 85.83%
$108 Results of Meeting 26 Nov 2018 5:12PM $1.150 $0.180 fallen by 84.35%
$108 Paradigm's AGM Presentation 26 Nov 2018 12:29PM $1.100 $0.180 fallen by 83.64%
$108 Paradigm in-licenses treatment for rare joint disease 22 Nov 2018 8:29AM $0.880 $0.180 fallen by 79.55%

526 - 550 of 721 results

Page 22 of 29

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.